The United States has initiated a formal investigation into Germany’s pharmaceutical pricing policies, specifically examining allegations of persistent underpayment for innovative drugs. The probe, conducted under Section 301 of the Trade Act of 1974, aims to ascertain whether Germany’s practices are unreasonable, discriminatory, or impose a burden on United States commerce.
US Trade Representative Jamieson Greer stated that the investigation follows “months of meaningful discussions with our German partners in an effort to resolve this issue.” He emphasised that the administration’s stance is that “American patients should not be shouldering a disproportionate share of global pharmaceutical research and development.” Greer expressed particular concern over reports that Germany is fast-tracking legislation intended to further reduce its expenditure on innovative pharmaceuticals, characterising this as a “serious step backwards at a time when our trading partners need to step up and start paying their fair share to fund innovative pharmaceutical research and development.”
The US Trade Representative’s office will open a public docket for written comments on June 25, with a public hearing scheduled for September before its Section 301 Committee. This action comes against a backdrop of significantly higher prescription drug prices in the United States compared to other developed nations. A 2024 RAND Corporation report indicated that US prices averaged 2.78 times higher than those in 33 other countries, with a more pronounced disparity for brand-name drugs.
Germany’s move to investigate its pharmaceutical pricing is reportedly linked to its efforts to address a healthcare funding gap. In April, the German Cabinet approved a healthcare draft law, described by Chancellor Friedrich Merz as “historic,” which aims to lower insurance premiums by generating savings exceeding €16 billion. However, these reforms have already drawn criticism from investors. Notably, US pharmaceutical giant Eli Lilly recently announced a decision to halve its planned €2.3 billion ($2.7 billion) investment in Alzey, Rhineland-Palatinate, citing the German government’s healthcare reforms as the reason for the reduced commitment.
Further complicating the situation, Reuters reported on Monday, citing a government source, that the German government is reconsidering plans to introduce variable discounts on pharmaceutical products. The Federal Health Ministry has stated that no final decisions have been made and declined to comment further on ongoing “parliamentary deliberations.” The implications of this investigation and Germany’s domestic healthcare reforms are significant for pharmaceutical companies, investors, and legal counsel navigating international trade agreements and regulatory landscapes.
... US Launches Section 301 Probe into Germany’s Pharmaceutical Pricing Practices ... Naijaonpoint.